← Evidence map

ArticleFrontiers in medicine2026

A phase 1, single-center, randomized, dose finding study to evaluate the safety, tolerability, and immunogenicity of a prophylactic COVID-19 pDNA vaccine after single ascending doses in healthy adults.

Iman Almansour-AlzamilPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

A phase 1, single-center, randomized, dose finding study to evaluate the safety, tolerability, and immunogenicity of a prophylactic COVID-19 pDNA vaccine after single ascending doses in healthy adults. | OpenQuestion